Form 4: Cargo Therapeutics CEO Gina Chapman Reports Stock Option Grant

Gina Chapman, CEO of Cargo Therapeutics, reports the acquisition of stock options.

Summary

• Gina Chapman, the President and CEO of Cargo Therapeutics, Inc., filed a Form 4 on March 4, 2024, reporting a transaction that occurred on March 1, 2024.
• Chapman acquired a stock option to purchase 400,000 shares of Cargo Therapeutics common stock at an exercise price of $25.07.
• The options vest monthly, with 1/48th of the shares vesting each month starting from January 1, 2024, and will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management with shareholder interests.

Positives

• The grant of stock options to the CEO aligns her interests with those of the shareholders, incentivizing her to increase the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management incentives with shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are typically benchmarked against peer companies in the biotechnology sector.
• The size and vesting schedule of the option grant would be compared to similar grants at companies of comparable size and stage of development, such as those in the XBI ETF.

Stakeholder Impact

• Shareholders: The stock option grant aligns the CEO's interests with increasing shareholder value.
• Employees: The grant could have a positive impact on employee morale as it signals confidence in the company's future.

Key Dates